Improving treatment planning for recurrent colorectal cancer using MRI
Official title: Investigating the Origins of Pelvic Recurrence in Colorectal Cancer
Run by Imperial College London · NCT02292641 · Data updated 2026-11-12
This study is testing a new way to use MRI scans to help doctors plan better treatments for patients with recurrent colorectal cancer.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 16 Years and up |
| Sex | All |
| Enrollment | 383 (estimated) |
| Sponsor | Imperial College London Academic / other |
| Locations | 4 sites (Oslo and 3 other locations) |
| Status | Recruiting |
| Started | September 25, 2014 |
| Main results expected | December 2026 |
| Study ends | December 2031 |
| Registry record updated | October 17, 2024 |
| Trial ID | NCT02292641 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals aged 16 and over with a confirmed diagnosis of recurrent pelvic colorectal cancer who have previously undergone surgical treatment for primary adenocarcinoma.
✕Probably not a fit
Patients with irresectable extra-pelvic metastatic disease or those without available original staging scans will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to enhance surgical and treatment planning for patients with recurrent colorectal cancer by implementing a new radiological staging classification system. It involves both prospective and retrospective assessments of patients' original primary tumor scans and surgical specimens to identify risk factors for recurrence. Participants will undergo high-resolution MRI for staging, and their treatment outcomes will be monitored over a three-year follow-up period. The study seeks to improve understanding of disease recurrence and optimize treatment strategies.
Why it matters
Potential benefit: If successful, this approach could lead to more effective treatment planning and improved outcomes for patients with recurrent colorectal cancer.
How similar studies have gone: Other studies have shown promise in using advanced imaging techniques for cancer staging, suggesting that this approach may yield beneficial results.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Had a primary colorectal adenocarcinoma proven by biopsy taken as part of routine clinical practice 2. Has a confirmed diagnosis of recurrent pelvic colorectal cancer 3. Has previously completed surgical treatment of primary adenocarcinoma of the colon, sigmoid colon or rectum 4. Are able to undergo high resolution MRI for staging prior to treatment decisions 5. Have provided written informed consent to participate in the study 6. Be aged 16 years or over Exclusion Criteria: 1. Have irresectable extra-pelvic metastatic disease 2. Original baseline staging and preoperative restaging scans (MR for rectal and sigmoid cancers and/or CT for colon and sigmoid cancers) are unavailable 3. Original preoperative, surgical and adjuvant treatment has not been documented or is unavailable
Where it's running
-
Oslo University Hospital
Oslo, Norway Recruiting -
St Mark's Hospital
Harrow, London, United Kingdom Recruiting -
Churchill Hospital
Oxford, Oxfordshire, United Kingdom Recruiting -
Royal Marsden Hospital NHS Foundation Trust
Sutton, United Kingdom Recruiting
Study contacts
- Principal investigator: Gina Dr Brown, MD — Imperial College London
- Study coordinator: Caroline Martin
- Email: c.martin1@imperial.ac.uk
- Phone: +44 (0) 7749 655 817
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
TriAdeno and N-803 vaccine in early prostate cancer on active surveillance
A vaccine combo called TriAdeno plus the N-803 drug is being tested to see if it can help slow or stop growth in men with early-stage, low- to intermediate-risk prostate cancer who are being watched rather than treated right away.
-
Biobank for pancreatic adenocarcinoma research
This study is collecting samples and information from people with pancreatic cancer to help find better ways to diagnose and treat the disease.
-
Using vorolanib for treating advanced kidney cancer
This study is testing if the drug vorolanib can help people with advanced kidney cancer live longer when used as a second treatment option.
-
Treatment with STAR0602 for advanced solid tumors
This study is testing a new treatment called STAR0602 to see if it can help people with advanced solid tumors by looking at how safe it is and how well it works.
-
Evaluating MRI and biopsy methods for prostate cancer detection
This study is testing whether a new type of MRI and a different way to do biopsies can help find prostate cancer more accurately in men who might have it.
-
HR20013 for preventing nausea and vomiting in cancer patients receiving chemotherapy
This real-world study tests whether HR20013 helps prevent nausea and vomiting in adults with cancer who are getting chemotherapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.